drugset / Trial / NCT01152203
Bendamustine and Bevacizumab for Advanced Cancers
Phase 1
Completed
59 enrolled
M.D. Anderson Cancer Center
Cephalon · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.
Timeline
- Start
- 2010-06
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
Indications
No indication recorded.